Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies

Fecha de publicación: 01/03/2017

Autores de IIS La Fe

Vicente Enrique Villanueva Haba

Autor

Participantes ajenos a IIS La Fe

Shorvon, SD
Trinka, E
Steinhoff, BJ
Holtkamp, M
Peltola, J
Ben-Menachem, E

Abstract

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is rapidly metabolized to its active metabolite, eslicarbazepine, which acts primarily by enhancing slow inactivation of voltage-gated sodium channels. The efficacy and safety/tolerability of ESL in the adjunctive setting were established in a comprehensive Phase III program (n = 1702 randomized patients) and this evidence has been supported by several open studies (n = 864). ESL treatment has demonstrated improvements in health-related quality of life, in both randomized clinical trials and open studies. ESL has also been shown to be usually well tolerated and efficacious when used in the adjunctive setting in elderly patients. The effectiveness of ESL as the only add-on to antiepileptic drug monotherapy has been demonstrated in a multinational study (n = 219), subgroup analyses of which have also shown it to be efficacious and generally well tolerated in patients who had previously not responded to carbamazepine therapy. Open studies have also demonstrated improvements in tolerability in patients switched overnight from oxcarbazepine to ESL. Due to differences in pharmacokinetics, pharmacodynamics, and metabolism, there may be clinical situations in which it is appropriate to consider switching patients from oxcarbazepine or carbamazepine to ESL.

Datos de la publicación

ISSN/ISSNe:: 0340-5354, 1432-1459
Tipo:: Review
Páginas:: 421-431
DOI:: 10.1007/s00415-016-8338-2
PubMed:: 28101651
Factor de Impacto:: 1,626 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Shorvon, SD:: UCL Institute of Neurology, Box 5, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK.

UCL Inst Neurol, Natl Hosp Neurol & Neurosurg, Box 5,Queen Sq, London WC1N 3BG, England
Trinka, E:: Department of Neurology and Neuroscience Institute at Christian Doppler Klinik, Paracelsus Medical University Salzburg, Ignaz Harrerstrasse 79, 5020, Salzburg, Austria

Centre for Cognitive Neuroscience, 5020, Salzburg, Austria

Paracelsus Med Univ Salzburg, Christian Doppler Klin, Dept Neurol, Ignaz Harrerstr 79, A-5020 Salzburg, Austria

Paracelsus Med Univ Salzburg, Christian Doppler Klin, Neurosci Inst, Ignaz Harrerstr 79, A-5020 Salzburg, Austria

Ctr Cognit Neurosci, A-5020 Salzburg, Austria
Steinhoff, BJ:: Epilepsiezentrum Kork, Landstraße 1, 77694, Kehl-Kork, Germany

Epilepsiezentrum Kork, Landstr 1, D-77694 Kehl, Germany
Holtkamp, M:: Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany

Charite Univ Med Berlin, Epilepsy Ctr Berlin Brandenburg, Dept Neurol, Charitepl 1, D-10117 Berlin, Germany
Villanueva, V:: Multidisciplinary Epilepsy Unit, Neurology Service, Hospital Universitario y Polotécnico La Fe, Avda Fernando Abril Martorell 106, 46026, Valencia, Spain

Hosp Univ & Polotecn La Fe, Multidisciplinary Epilepsy Unit, Neurol Serv, Avda Fernando Abril Martorell 106, Valencia 46026, Spain
Peltola, J:: Department of Neurology, Tampere University Hospital, PO Box 2000, 33521, Tampere, Finland

Tampere Univ Hosp, Dept Neurol, POB 2000, Tampere 33521, Finland
Ben-Menachem, E:: Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Göteborg, Box 430, SE-405 30, Göteborg, Sweden

Univ Goteborg, Sahlgrenska Acad, Inst Neurosci & Physiol, Box 430, SE-40530 Gothenburg, Sweden